SG Americas Securities LLC Has $381,000 Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

SG Americas Securities LLC lowered its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 88.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,989 shares of the medical device company's stock after selling 68,658 shares during the period. SG Americas Securities LLC's holdings in Tandem Diabetes Care were worth $381,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Tandem Diabetes Care by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 7,021,906 shares of the medical device company's stock valued at $207,708,000 after purchasing an additional 18,571 shares during the period. PNC Financial Services Group Inc. grew its position in Tandem Diabetes Care by 79.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 5,788 shares of the medical device company's stock valued at $171,000 after acquiring an additional 2,562 shares during the period. GAMMA Investing LLC raised its stake in Tandem Diabetes Care by 55.7% during the first quarter. GAMMA Investing LLC now owns 3,845 shares of the medical device company's stock worth $136,000 after acquiring an additional 1,375 shares in the last quarter. Park Avenue Securities LLC lifted its holdings in shares of Tandem Diabetes Care by 20.3% during the first quarter. Park Avenue Securities LLC now owns 8,650 shares of the medical device company's stock valued at $306,000 after acquiring an additional 1,459 shares during the period. Finally, MCF Advisors LLC boosted its stake in shares of Tandem Diabetes Care by 79.3% in the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company's stock valued at $36,000 after purchasing an additional 445 shares in the last quarter.

Tandem Diabetes Care Stock Performance

Shares of NASDAQ:TNDM opened at $35.34 on Friday. The stock has a market capitalization of $2.31 billion, a P/E ratio of -16.91 and a beta of 1.33. The company has a current ratio of 3.05, a quick ratio of 2.38 and a debt-to-equity ratio of 1.31. Tandem Diabetes Care, Inc. has a 1-year low of $13.82 and a 1-year high of $53.69. The business has a 50-day moving average price of $41.98 and a two-hundred day moving average price of $41.85.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The medical device company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07. Tandem Diabetes Care had a negative net margin of 17.15% and a negative return on equity of 41.54%. The business had revenue of $221.90 million during the quarter, compared to the consensus estimate of $205.63 million. During the same period in the previous year, the firm posted ($0.30) earnings per share. Tandem Diabetes Care's revenue for the quarter was up 13.3% compared to the same quarter last year. Equities analysts predict that Tandem Diabetes Care, Inc. will post -1.76 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on TNDM shares. Morgan Stanley reiterated an "equal weight" rating and set a $45.00 target price on shares of Tandem Diabetes Care in a research report on Monday, September 23rd. Robert W. Baird lifted their target price on shares of Tandem Diabetes Care from $36.00 to $39.00 and gave the company a "neutral" rating in a research note on Friday, August 2nd. Wells Fargo & Company boosted their target price on Tandem Diabetes Care from $50.00 to $55.00 and gave the stock an "overweight" rating in a report on Friday, August 2nd. Canaccord Genuity Group assumed coverage on Tandem Diabetes Care in a report on Thursday, August 8th. They set a "buy" rating and a $57.00 price target for the company. Finally, Barclays lifted their price objective on Tandem Diabetes Care from $55.00 to $58.00 and gave the company an "overweight" rating in a research report on Monday, August 5th. Five research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $55.13.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.